Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
In vivo effects of interleukin 3 in HIV type 1-infected patients with cytopenia.
AIDS Res Hum Retroviruses. 1995 Jun;11(6):731-40. Unique Identifier : AIDSLINE MED/96078234 Scadden DT; Levine JD; Bresnahan J; Gere J; McGrath J; Wang Z; Resta DJ; Young D; Hammer SM; Division of Hematology/Oncology, New England Deaconess Hospital,; Harvard Medical School, Boston, Massachusetts 02215, USA.
Abstract:
OBJECTIVE: To determine the safety, tolerance, and hematological and virological effects of the recombinant hematopoietic growth factor interleukin 3 (IL-3) in HIV-1-infected individuals with cytopenia. DESIGN AND METHODS: A phase I single-center trial was conducted with patients in cohorts of three receiving one of four dose levels of self-administered, subcutaneously injected IL-3 (0.5, 1.0, 2.5, or 5.0 micrograms/kg/day). Toxicities, hematological effects, and virological effects were recorded. Viral studies included serum HIV p24 antigen levels, quantitative plasma and peripheral blood mononuclear cell cultures, and quantitative, competitive polymerase chain reaction of patient plasma. RESULTS: Increases in white blood cell counts (WBC) and absolute neutrophil counts (ANC) were noted at the higher dose levels while absolute eosinophil counts (AEC) increased in all patients. The percent changes in WBC from baseline ranged from 52 to 309 and in ANC from 20 to 262 in the 2.5- and 5.0-micrograms/kg/day groups. The mean AEC change was 17-fold (range, 2- to 59-fold). Hemoglobin, hematocrit, platelets, and CD4 and CD8 counts were generally unaffected although individual patients demonstrated increases in hemoglobin and platelet levels. Toxicities were generally mild, but one patient developed a transient local erythematous rash at the sites of IL-3 injection which pathologically demonstrated hypersensitivity vasculitis. Of note, viral studies did not demonstrate any consistent changes in HIV-1 activity. CONCLUSION: These data demonstrate limited hematological effects of IL-3 monotherapy in HIV-1-infected patients with cytopenia. However, should IL-3 be incorporated into combination cytokine therapies for HIV disease, these data suggest that IL-3 does not enhance in vivo HIV-1 activity.
Keywords: Adult Blood Cell Count Cohort Studies Human HIV Core Protein p24/ANALYSIS HIV Infections/*COMPLICATIONS *HIV-1 Interleukin-3/ADVERSE EFFECTS/*THERAPEUTIC USE Leukocytes, Mononuclear/VIROLOGY Leukopenia/COMPLICATIONS/*DRUG THERAPY Male Middle Age Polymerase Chain Reaction/METHODS Recombinant Proteins/ADVERSE EFFECTS/THERAPEUTIC USE RNA, Viral/BLOOD Virus Cultivation CLINICAL TRIAL CLINICAL TRIAL, PHASE I JOURNAL ARTICLE 960228
M9621016
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
